Tridural(TM) Provides New Option for the Treatment of Pain in Canada
MONTREAL and LAVAL, QC, Sept. 17 /CNW/ - Paladin Labs Inc. (TSX:PLB) and
Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced the Canadian launch of
Tridural(TM) once-daily tramadol product. Tridural(TM) is a unique treatment
option developed as a first-line therapy for adult patients with moderate pain
who require treatment for several days or more that provides 24-hour pain
relief from a single tablet taken once-daily.
Tridural(TM) is based on Labopharm's proprietary controlled-release
technology, Contramid(R), and a novel dual matrix delivery system that
facilitates both rapid and sustained drug release, maintaining therapeutic
blood levels of tramadol for a full 24-hour period. Tridural(TM) offers
physicians and patients greater treatment flexibility based on its relatively
rapid two-day titration schedule, which could help patients reach their
optimum daily dose faster than any other approved once-daily tramadol product
and quickly achieve effective pain relief. In addition, Tridural(TM) has a
demonstrated safety profile based on clinical trial experience of more than
2,400 patients globally and almost two years of commercial experience. As a
tramadol product, Tridural(TM) provides pain relief through its action at
three sites related to analgesic activity: the micro-opioid receptor, the
serotonin receptor, and the norepinephrine receptor.
"The largest component of the pain market is composed of patients with
persistent, moderate pain. Tridural(TM) is a new treatment option that
specifically addresses this large group. Based on our market research,
Tridural(TM) has some unique advantages over its competitors. We are excited
to launch Tridural(TM) to the benefit of Canadian patients," said Jonathan
Ross Goodman, President and Chief Executive Officer of Paladin Labs Inc.
"Tridural(TM)'s competitive strengths - full 24-hour pain relief,
titration flexibility and demonstrated safety profile - are directly
attributable to Labopharm's Contramid(R) technology, which was developed to
optimize the performance of existing drug products," said James R.
Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "As a
Contramid(R) technology-based product, Tridural(TM) will be significantly
differentiated in the marketplace."
Acute pain is usually of short duration, results from tissue damage due
to an injury or surgery and serves as a protective mechanism. When tissue is
damaged, free nerve endings in the skin send signals to the brain via the
spinal cord. Chronic pain is defined as pain that persists over three months.
Chronic pain can be intermittent (occurs in a pattern) or persistent (lasting
more than 12 hours daily) and can be considered a disease itself. Chronic pain
can result from a known cause, such as arthritis, or from abnormal processing
of pain by the nervous system as in the case of fibromyalgia. According to IMS
Canada, in 2006 the Canadian prescription pain market was $800 million and
reached almost 26 million prescriptions. It is estimated that one in five
Canadians have chronic pain that interferes with their quality of life and
About Labopharm's Once-Daily Tramadol Product
Labopharm's once-daily tramadol product is based on the Company's
proprietary Contramid(R) technology and provides a dual matrix delivery system
allowing both rapid and sustained drug release that maintains blood levels
within the therapeutic range providing a full 24 hours of pain relief. The
Company believes that maintaining drug concentrations within the therapeutic
range could have the advantage of fewer and less severe side effects while
maintaining efficacy. Under its global commercialization program, Labopharm's
once-daily tramadol product has been approved in 28 countries and a global
product launch is underway.
Tramadol is a centrally acting analgesic for the treatment of moderate to
severe pain. Tramadol has a 30-year history of efficacy and safety and is
currently marketed in more than 70 countries worldwide, primarily in
formulations that require multiple doses per day. Studies have shown that
tramadol provides relief from both acute and chronic pain conditions,
including osteoarthritis pain, low back pain, cancer pain, post-operative pain
and dental pain. Tramadol avoids the potentially serious side effects such as
gastrointestinal bleeding that may be caused by NSAIDs and the potential
cardiovascular events recently attributed to COX-2 inhibitors. Compared to
stronger opioids, tramadol has, in clinical studies, demonstrated a lower
incidence of major side effects, such as respiratory depression.
About Paladin Labs Inc.
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty
pharmaceutical company focused on acquiring or in-licensing innovative
pharmaceutical products for the Canadian market. With this strategy, a focused
national sales team and proven marketing expertise, Paladin has evolved into
one of Canada's leading specialty pharmaceutical companies. For more
information, please visit the Company's web site at www.paladinlabs.com.
About Labopharm Inc.
Labopharm is an emerging leader in optimizing the performance of existing
small molecule drugs using its proprietary controlled-release technologies.
The Company's lead product, a unique once-daily formulation of tramadol, is
being commercially launched in key markets globally. The Company has a robust
pipeline of follow-on products in both pre-clinical and clinical development.
Labopharm's vision is to become a fully integrated, international, specialty
pharmaceutical company with the capability to internally develop and
commercialize its own products. For more information, please visit
These forward-looking statements, by their nature, necessarily involve
risks and uncertainties that could cause actual results to differ materially
from those contemplated by the forward-looking statements. The Companies
consider the assumptions on which these forward-looking statements are based
to be reasonable at the time they were prepared, but caution that these
assumptions regarding the future events, many of which are beyond the control
of the Companies and their subsidiaries, may ultimately prove to be incorrect.
Factors and risks, which could cause actual results to differ materially from
current expectations, are discussed in the annual reports, as well as in the
Companies' Annual Information Forms for the year ended December 31, 2006. The
Companies disclaim any intention or obligation to update or revise any
forward-looking statements whether a result of new information, future events,
or except as required by law. For additional information on risks and
uncertainties relating to these forward-looking statements, investors should
consult the Companies' ongoing quarterly filings, annual reports and Annual
Information Forms and other filings found on SEDAR at www.sedar.com.
For further information:
For further information: At Paladin Labs Inc.: Samira Sakhia, Chief
Financial Officer, (514) 340-5067, (514) 344-4675 (FAX),
email@example.com, www.paladinlabs.com; At Labopharm Inc.: Mark D'Souza,
Chief Financial Officer, Tel: (450) 686-0207; At The Equicom Group: Jason
Hogan, Media and Investor Relations, Tel: (416) 815-0700,
firstname.lastname@example.org; French: Eric Bouchard, Tel: (514) 844-7997,